You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 1, January 1981 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (24)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Continuous Infusion of Lidocaine in Patients With Cardiac Arrhythmias

Unpredictability of Plasma Concentrations

Dennis R. Sawyer, PharmD; Thomas M. Ludden, PhD; Michael H. Crawford, MD

Arch Intern Med. 1981;141(1):43-45.


Abstract

{dagger} Recent studies suggest that lidocaine hydrochloride continues to accumulate during prolonged infusions. Plasma levels of lidocaine and monoethylglycinexylidide (MEGX) were measured in 26 patients with cardiac arrhythmias during lidocaine infusions of 15 to 69 hours' duration. Clearance varied, ranging from 3.2 to 14.7 mL/min/kg, and was significantly less in the ten patients with heart failure (5.8 ±1.7 mL/min/kg) as compared with the remaining 16 (8.4 ± 2.6 mL/min/kg; P <.05). The MEGX levels were <1 µ/mL. In four patients, steady states were achieved at two different infusion rates, and changes in lidocaine plasma levels were generally proportional to changes in infusion rates. Lidocaine elimination half-lives ranged from 3.2 to 8.7 hours, and no accumulation continued beyond four half-lives. Clearance values, elimination half-lives, apparent volumes of distribution, and, consequently, steady-state levels were widely variable, which can be partly explained by the inclusion of patients with congestive heart failure. Monitoring of serum lidocaine levels may aid in individualization of therapy.

(Arch Intern Med 141:43-45, 1981)



Author Affiliations

From the Veterans Administration Hospital (Drs Sawyer, Ludden, and Crawford), and the Divisions of Clinical Pharmacology (Dr Ludden) and Cardiology (Dr Crawford), Department of Medicine, University of Texas Health Science Center, San Antonio; and the College of Pharmacy, University of Texas, Austin (Drs Sawyer and Ludden).


Footnotes

Accepted for publication Feb 20, 1980.

Reprint requests to Department of Medicine, University of Texas Health Science Center, 7703 Floyd Curl Dr, San Antonio, TX 78284 (Dr Crawford).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

An Undocumented Effect of Lidocaine Revealed by Computerized Electrocardiography
Leor et al.
ANGIOLOGY 1993;44:517-522.
ABSTRACT  

Simple Method for Maintaining Serum Lidocaine Levels in the Therapeutic Range
Wong and Hurwitz
Arch Intern Med 1985;145:1588-1591.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.